Skip to main content

Table 1 Summary of the obtained results for CJD and non-CJD cases

From: Proteinase-activated receptor 2 and disease biomarkers in cerebrospinal fluid in cases with autopsy-confirmed prion diseases and other neurodegenerative diseases

Cases n Male/Female Disease duration [months] Age at death [years] PAR-2 [ng/ml] T-tau [pg/ml] P-tau [pg/ml] [pg/ml] 14-3-3
P W N
CJD 36 12/24 6.8 ± 8.3 [1–48] 63.1 ± 8.3 [39–81] 8.78 ± 6.40 [1.25–28.49] 1111.47 ± 264.48 [195–1201] 52.69 ± 30.86 [16–166] 619.39 ± 297.34 [212–1407] 21 7 8
non-CJD 23 15/8 24.1 ± 22.2 [2–84] 71.0 ± 10.4 [53–90] 9.31 ± 8.71 [1.22–41] 632.43 ± 434.03 [65–1201] 47.48 ± 28.38 [15–103] 561.22 ± 421.20 [94–1672] 4 3 16
  AD 6 4/2 28.67 ± 29.87 [2–84] 70 ± 10.66 [54–82] 13.26 ± 14.62 [1.22–41] 926.83 ± 366.99 [268–1201] 53.83 ± 27.67 [29–102] 401 ± 409.04 [94–1109] 1 2 3
  FTLD-TDP 11 7/4 17.2 ± 14.86 [3–46] 70.8 ± 11.4 [53–90] 8.15 ± 5.96 [1.73–21.79] 558.27 ± 424.44 [134–1201] 39.10 ± 24.35 [15–94] 517.64 ± 241.35 [265–1065] 2 0 9
  VD 4 3/1 27.5 ± 31 [2–72] 70.5 ± 7.1 [62–79] 5.03 ± 1.61 [2.79–6.44] 547 ± 521.99 [65–1201] 52.25 ± 38.45 [20–103] 945 ± 755.50 [186–1672] 1 1 2
  PSP 2 1/1 38 ± 2.83 [36–40] 76.5 ± 17.68 [64–89] 12.36 ± 6.05 [8.08–16.64] 328 ± 239 [159–497] 65 ± 42.43 [35–95] 514 ± 55.15 [475–553] 0 0 2
  1. Results are shown as mean ± S.D. [min–max]; P – positive, W – weakly positive, N – negative. AD – Alzheimer’s disease; FTLD-TDP – frontotemporal lobar degeneration with TDP-43 inclusions; PSP – progressive supranuclear palsy; VD – vascular dementia.